Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 159 of the 161 references it cites were found in a registry or an index.

Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility

Open access

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual GLP-1- and glucose-dependent insulinotropic polypeptide receptor co-agonist tirzepatide (referred to here collectively as “GLP-1-based therapy”) are incretin-based therapies being used increasingly in the management of both type 2 diabetes and obesity. They are now recognized to have beneficial effects beyond improved glycemic control and weight loss, including cardiovascular and renal protection. GLP-1-based therapy also slows gastric emptying, which has benefits (lowering postprandial glucose), but also potential risks (eg, hypoglycemia in individuals on insulin or sulphonylurea therapy). Their effects on the gallbladder may also be beneficial, contributing to reducing postprandial triglycerides, but they also potentially increase the risk of biliary disease. In this review, we summarize the effects of GLP-1 and incretin-based therapeutics on gastric, biliary and small intestinal function. An improved understanding of these effects will optimize the use of these drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/endocr/bqae155

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Factors that slow or accelerate gastric emptying.
Figure 1. Factors that slow or accelerate gastric emptying.CC BY · PubMed Central
Figure 2. Techniques frequently used to measure gastric emptying.
Figure 2. Techniques frequently used to measure gastric emptying.CC BY · PubMed Central
Figure 3. Intragastric retention of a 300-mL drink containing 75-g glucose at (A) 120 minutes and (B) 240 minutes after ingestion in 30 participants with T2D after 8 weeks treatment with either lixisenatide 20 µg (n = 15) or placebo (n = 15). Median values are indicated. Lixisenatide substantially slows gastric emptying of liquids at 120 minutes and 240 minutes. Reproduced from Kovoor et al (50). © 2024 The Authors. Published by Elsevier Inc.
Figure 3. Intragastric retention of a 300-mL drink containing 75-g glucose at (A) 120 minutes and (B) 240 minutes after ingestion in 30 participants with T2D after 8 weeks treatment with either lixisenatide 20 µg (n = 15) or placebo (n = 15). Median values are indicated. Lixisenatide substantially slows gastric emptying of liquids at 120 minutes and 240 minutes. Reproduced from Kovoor et al (50). © 2024 The Authors. Published by Elsevier Inc.CC BY · PubMed Central
Figure 4. Mechanisms for the effect of GLP-1/GLP-1RA on gallbladder and gastrointestinal motility.
Figure 4. Mechanisms for the effect of GLP-1/GLP-1RA on gallbladder and gastrointestinal motility.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 161 references

Research works printed but not linked: 1

  1. Jalleh, 2024, [Abstract] short-acting glucagon-like peptide-1 receptor agonist therapy delays gastric emptying during insulin-induced hypoglycaemia as well as euglycaemia in type 2 diabetes, Diabetologia, 67, S45

Cited by

See all 61

Metadata

Authors
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M.
Affiliations
  • Royal Adelaide Hospital (AU)
  • The University of Adelaide (AU)
  • St. Josef-Hospital (DE)
  • Universitätsmedizin Greifswald (DE)
Corresponding author
Horowitz, Michael
Venue
Endocrinology
Published
2024-11-21
Volume
166
Issue
1
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W4404599306
Cited by
61
References
161
Citations by year
2026: 42 · 2025: 19
FWCI
3.57
Type
journal article
Language
en
Open access
Locations
  • Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UniSA Research Outputs Repository (University of South Australia) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
GLP-1 receptor agonists, tirzepatide, incretin-based therapy, gastric emptying, gallbladder motility, biliary function, small intestine motility, type 2 diabetes, obesity, postprandial triglycerides, hypoglycemia, biliary tract diseases, gastrointestinal adverse effects
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Biliary Tract, Diabetes Mellitus, Type 2, Gastric Emptying, Gastrointestinal Motility, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. https://app.cochat.ai/papers/10.1210/endocr/bqae155
The paper
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024). Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. Endocrinology. https://doi.org/10.1210/endocr/bqae155

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.